IMNN:NASDAQImunon, Inc. Analysis

Imunon, Inc. (IMNN) is trading at a price far below its own internal valuation targets, with the market price hovering just above the 20‑day SMA and comfortably under the 50‑day SMA, suggesting a modest upward drift despite severe downside pressure.
The technical picture is mixed: the 14‑day RSI sits deep in oversold territory, the MACD histogram has just turned positive and the MACD line and signal line are both negative but converging, and the 30‑day volatility sits near 41 % while volume trends are decreasing, all of which point to a fragile but potentially rebounding short‑term setup.
Fundamentally, the company shows a negative PE, zero dividend, a massive historical drawdown of roughly ‑89 %, a low beta indicating limited market‑wide risk, and an extreme greed reading on the fear/greed index, while its biotech sector carries high regulatory and clinical‑trial risk, making the overall risk profile elevated.